Erratum

Erratum for the Research Article: “The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study” by P. Kiessling, R. Lledo-Garcia, S. Watanabe, G. Langdon, D. Tran, M. Bari, L. Christodoulou, E. Jones, G. Price, B. Smith, F. Brennan, I. White, S. Jolles

See allHide authors and affiliations

Science Translational Medicine  06 Dec 2017:
Vol. 9, Issue 419, eaar6448
DOI: 10.1126/scitranslmed.aar6448

In the manuscript “The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study,” authors noted a minor error in the plot headings for Fig. 3, panels A and B. Figure 3A should read “Route of administration: IV,” and Fig. 3B should read “Route of administration: SC,” as per the Fig. 3 legend. The PDF and HTML (full text) have been corrected.

Navigate This Article